blinatumomab

Ligand id: 7384

Name: blinatumomab

View interactive charts of activity data from ChEMBL and GtoPdb across species (New!)

Bioactivity Comments
The development of blinatumomab is covered by patent US7635472 [3], based on peptide sequence matches of the two antigen-binding variable heavy chains regions of blinatumomab. In this patent specificity and efficacy of blinatumomab binding was determined by FACS analysis and ELISA. However, the specific clone producing blinatumomab is not reported, nor are binding affinity values for antibody-antigen interactions
Selectivity at human other protein targets
Key to terms and symbols Click column headers to sort
Target Type Action Affinity Units Concentration range (M) Reference
CD19 Antibody Binding 9.0 pKd - 2
pKd 9.0 (Kd 1x10-9 M) [2]
Description: Binding of the single-chain Fv portion of blinatumomab to CD19.
CD3e Antibody Binding 7.0 pKd - 2
pKd 7.0 (Kd 1x10-7 M) [2]
Description: Binding of the single-chain Fv portion of blinatumomab to CD3.